These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 14676228)

  • 21. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sulfonylurea treatment in type 2 diabetes.
    Bester K; Ton J; Korownyk C
    Can Fam Physician; 2018 Apr; 64(4):295. PubMed ID: 29650607
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical effects of ischemic preconditioning.
    Schwarz ER; Reffelmann T; Kloner RA
    Curr Opin Cardiol; 1999 Jul; 14(4):340-8. PubMed ID: 10448615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controversies in management of diabetes in patients with coronary heart disease.
    Abdella NA
    Med Princ Pract; 2002; 11 Suppl 2():69-74. PubMed ID: 12444313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Increased cardiovascular risk in patients with type 2 diabetes treated with sulfonylurea?].
    Asvold BO; Jonsbu M; Grill V
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2560-4. PubMed ID: 11070997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sulfonylurea drugs and cardiovascular mortality.
    O'Keefe JH; McCallister BD; Blackstone EH
    J Am Coll Cardiol; 1999 Sep; 34(3):958. PubMed ID: 10483986
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
    Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
    Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of cardiac metabolism during myocardial ischemia.
    Chagas AC; Dourado PM; Galvão Tde F
    Curr Pharm Des; 2008; 14(25):2563-71. PubMed ID: 18991673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?
    Riddle MC
    J Clin Endocrinol Metab; 2003 Feb; 88(2):528-30. PubMed ID: 12574174
    [No Abstract]   [Full Text] [Related]  

  • 30. Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial.
    Khan AA; Chung MJ; Novak E; Brown DL
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28903941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of the ischaemic heart: investigations into the phenomenon of ischaemic preconditioning.
    Lochner A; Marais E; Genade S; Huisamen B; du Toit EF; Moolman JA
    Cardiovasc J Afr; 2009; 20(1):43-51. PubMed ID: 19287816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glipizide versus tolbutamide in maturity-onset diabetes, an open comparative study.
    Fuchs K
    Diabetologia; 1973 Sep; ():351-5. PubMed ID: 4772980
    [No Abstract]   [Full Text] [Related]  

  • 33. [Should the occurrence of a first coronary event change the management of diabetes?].
    Timsit J; Dubois-Laforgue D
    Arch Mal Coeur Vaiss; 2000 Dec; 93 Spec No 4():39-44. PubMed ID: 11296461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ischaemic preconditioning and cardiac surgery.
    Alkhulaifi AM; Jenkins DP; Pugsley WB; Treasure T
    Eur J Cardiothorac Surg; 1996; 10(9):792-8. PubMed ID: 8905283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
    Andersson C; Gislason GH; Jørgensen CH; Hansen PR; Vaag A; Sørensen R; Mérie C; Olesen JB; Weeke P; Schmiegelow M; Norgaard ML; Køber L; Torp-Pedersen C
    Diabetes Res Clin Pract; 2011 Oct; 94(1):119-25. PubMed ID: 21831467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
    Juurlink DN; Gomes T; Shah BR; Mamdani MM
    Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are sulfonylureas passé?
    Green JB; Feinglos MN
    Curr Diab Rep; 2006 Nov; 6(5):373-7. PubMed ID: 17076998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetic analysis of 99mTc-sestamibi evaluates the protective effects by ischaemic preconditioning on ischaemic myocardium in an isolated rabbit heart.
    Liang J; Chen HL; Zhou Y; Xie M; Xu LM; Lin G
    Nucl Med Commun; 2007 Nov; 28(11):864-9. PubMed ID: 17901770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.
    Nieszner E; Posa I; Kocsis E; Pogátsa G; Préda I; Koltai MZ
    Exp Clin Endocrinol Diabetes; 2002 Aug; 110(5):212-8. PubMed ID: 12148084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial.
    Hausenloy DJ; Mwamure PK; Venugopal V; Harris J; Barnard M; Grundy E; Ashley E; Vichare S; Di Salvo C; Kolvekar S; Hayward M; Keogh B; MacAllister RJ; Yellon DM
    Lancet; 2007 Aug; 370(9587):575-9. PubMed ID: 17707752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.